Atomo Diagnostics Unlocks 15x Bigger US Market as FDA Clears FebriDx for Pharmacies
Atomo Diagnostics secures major US market catalyst as FebriDx receives FDA CLIA waiver
Atomo Diagnostics (ASX: AT1) has announced that the FebriDx® CLIA waiver has been granted by the US Food and Drug Administration, opening access to a substantially expanded US market for the rapid diagnostic test. Atomo serves as the exclusive licensor, manufacturer and supplier of Pascal cassettes used in FebriDx®, a rapid test differentiating viral from bacterial infections. According to partner Lumos Diagnostics, the CLIA waiver is estimated to expand the US addressable market by approximately 15 times. The performance of Atomo’s patented Pascal cassette was pivotal in achieving this approval.
Under Atomo’s exclusive supply agreement with Lumos, which runs until 30 June 2031, every FebriDx® test sold requires Lumos to order an assembled Pascal cassette from Atomo. This regulatory clearance directly activates commercial upside through existing contracted arrangements, positioning Atomo to benefit from FebriDx®’s expanded market penetration across non-laboratory testing sites.
When big ASX news breaks, our subscribers know first
What is a CLIA waiver and why it matters for diagnostics companies
A CLIA waiver allows diagnostic tests to be performed in non-laboratory settings such as pharmacies, urgent care clinics and physician offices. This designation removes the requirement for certified laboratory personnel to administer the test, dramatically expanding where and how the product can be used commercially.
For FebriDx®, a rapid test that differentiates viral from bacterial infections, CLIA waiver status means the product can now reach significantly more point-of-care locations. Tests previously restricted to laboratory environments can transition to mass-market accessibility, fundamentally changing the revenue opportunity for all parties in the supply chain. This regulatory milestone transforms the commercial landscape by enabling deployment wherever rapid clinical decision-making is needed, without the infrastructure constraints of traditional laboratory testing.
Contracted revenues and Pascal supply economics
Atomo’s commercial position is defined by contractual arrangements now activated by the CLIA waiver approval. Lumos sells FebriDx® to PHASE Scientific under a July 2025 agreement, and every FebriDx® test requires a Pascal cassette ordered from Atomo. These supply chain mechanics are underpinned by committed minimums and shortfall fee protections.
| Metric | Value |
|---|---|
| PHASE agreement term | Six years |
| PHASE MOQs | Up to US$313 million in FebriDx® revenues |
| Pascal orders received since July 2025 | ~A$1.57 million |
| Committed Pascal revenues (post-CLIA waiver) | US$3.4 million (A$5.2 million) |
| Atomo-Lumos agreement expiry | 30 June 2031 |
The committed Pascal revenues of US$3.4 million (A$5.2 million) exclude intellectual property licensing payments already made by Lumos. Importantly, the volumes anticipated to support the PHASE agreement are a magnitude larger than the contract minimums between Atomo and Lumos. Under the exclusive supply agreement, Lumos committed to purchase annual Pascal volumes to secure ongoing exclusivity for the Pascal cassette’s use with FebriDx®, with a shortfall fee agreed if annual volumes are not met.
Atomo has locked-in minimum revenue commitments with additional upside tied to FebriDx® commercial success in the expanded US market.
Pascal platform validated for US regulatory pathway
The Pascal cassette’s role in achieving CLIA waiver approval serves as validation of the platform technology. Pascal delivers improved usability and reliability for untrained users, characteristics that proved essential in meeting the stringent requirements for waived testing status. This creates a referenceable case study for other diagnostic applications seeking similar regulatory pathways.
John Kelly, Managing Director
“We are delighted to see FebriDx® receive CLIA waiver approval and are proud of the critical role that Pascal played in that. We are now actively scaling up Pascal operations to support growing demand from Lumos and from other new pipeline customers, who have seen the outstanding performance that Pascal delivered for FebriDx, and its proven ability to support valuable CLIA waiver approvals in the US market.”
Pascal’s proven regulatory track record positions Atomo to attract additional diagnostic partners seeking CLIA waiver pathways, with the platform’s performance in FebriDx® studies providing concrete evidence of its capability to meet FDA requirements for non-laboratory use.
Scaling operations and pipeline expansion
Atomo is actively scaling Pascal operations to meet growing demand from both Lumos and new pipeline customers attracted by the platform’s FebriDx® performance. The company’s broader diagnostic applications span infectious disease and pregnancy detection, creating multiple commercialisation pathways for the validated technology.
- Immediate focus: scaling production capacity for Lumos orders supporting the PHASE agreement
- Near-term opportunity: converting pipeline customer interest into commercial agreements
- Platform validation: CLIA waiver success strengthens competitive positioning for new partnerships
Atomo has supply agreements in place for testing applications targeting HIV, COVID-19, viral versus bacterial differentiation, and early detection of pregnancy. The FebriDx® milestone serves as both immediate revenue catalyst and business development proof point for platform diversification across these applications.
The next major ASX story will hit our subscribers first
What this means for Atomo shareholders
The CLIA waiver approval represents a regulatory catalyst achieved, contracted revenues activated, and platform validated in a single milestone. The agreement structure provides revenue visibility through June 2031, with contracted minimums establishing a baseline regardless of broader commercialisation outcomes.
Execution risk relates to Lumos and PHASE commercialisation success in penetrating the expanded US market. However, the contracted minimums with shortfall fee protections provide downside protection, while the magnitude of anticipated volumes above these minimums offers substantial upside participation if FebriDx® captures market share in newly accessible point-of-care settings.
Atomo transitions from waiting on regulatory outcome to participating in commercial ramp, with contracted minimums de-risking near-term revenue trajectory while maintaining exposure to FebriDx® commercial success across an addressable market now 15 times larger than pre-approval.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they drop.